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Protein kinasesThe beta3 adrenergic receptor (B3-AR) reportedly induces cell proliferation, but the signaling pathways that
were proposed, involving either Gs or Gi coupling, remain controversial. To further investigate the role of G pro-
tein coupling in B3-AR induced proliferation, we stimulated primary human myometrial smooth muscle cells
with SAR150640 (B3-AR agonist) in the absence or presence of variable G-protein inhibitors. Speciﬁc B3-AR
stimulation led to an Erk1/2 induced proliferation. We observed that the proliferative effects of B3-AR require
two Erk1/2 activation peaks (the ﬁrst after 3 min, the second at 8 h). Erk1/2 activation at 3 min was mimicked
by forskolin (adenylyl-cyclase activator), and was resistant to pertussis toxin (Gi inhibitor), suggesting a Gs pro-
tein signaling. This ﬁrst signaling also required the downstream Gs signaling effectors PKA and Src. However,
Erk1/2 activation at 8 h turned out to be pertussis toxin-dependent, and PKA-independent, indicating a Gi signal-
ing pathway inwhich Src and PI3Kwere required. The pharmacological inhibition of both the Gs and Gi pathway
abolished B3-AR-inducedproliferation. Altogether, these data indicate that B3-AR-inducedproliferation depends
on the biphasic activation of Erk1/2 sequentially induced by the Gs/PKA/Src and Gi/Src/PI3K signaling pathways.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
First identiﬁed in the brown adipose tissue [1], the beta3 isoform
of adrenergic receptor (B3-AR) has been extensively studied for its
potential interest in the treatment of obesity and type II diabetes. Fur-
ther work demonstrated its expression in other tissues, such as the
brain, retina, urinary bladder, prostate, and blood vessels. These ﬁnd-
ings opened the way for new potential therapies for different condi-
tions such as bladder instability, hypertension, or depression [2,3].
B3-AR is a G protein coupled receptor (GPCR) that can be coupled
to a Gs [4–6] or a Gi protein [7,8]. In smooth muscle cells, B3-AR,
like other beta-adrenergic receptors, is most commonly reported to
be positively coupled to a Gs protein, leading to the activation of ade-
nylate cyclase, the production of cyclic AMP (cAMP) and subsequent
relaxation [4,9].803, CHU de Dijon, Faculté de
dex, France. Tel.: +33 3 80 39
Lirussi).
rights reserved.We previously described the expression of B3-AR in human
near-term myometrium, the smooth muscle layer of the uterus, where
it is able to induce cAMP-dependent relaxation via Gs protein coupling
[4,10–12]. Moreover, the B3-AR is also able to inhibit the production of
cytokines (such as TNFα, IL-6, and IL-8) to prevent not only myometrial
cell apoptosis [13] but also extracellular matrix remodeling [14], two
common features of uterine preparation for labor onset [15–19]. Another
common feature of labor onset is the switch in the phenotype of
myometrial smooth muscle cells from a proliferative to a hypertrophic
state,which allows the synthesis of contractilematerial [20].Maintaining
uterine smooth muscle cells in a proliferative state could therefore be a
promising target for the prevention of preterm labor.
The B3-AR is able to induce the proliferation of several cell types
(choroidal cells, brown adipose tissue cells, airway smooth muscle
cells, and neuronal progenitors) [8,21–24] via the transient activation
of Erk1/2. However, the signaling downstream of B3-AR stimulation,
which leads to Erk1/2 activation, still remains controversial since
B3-AR Gprotein coupling appears to be tissue-dependent. For exam-
ple, Bronnikov et al. [25] and Lindquist et al. [26] both proposed
Gs-coupling in brown adipocytes, while Steinle et al. [8], Anesini et
al. [21] and Robay et al. [27] proposed Gi-coupling in coroidal cells,
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spectively. Many studies have linked cAMP signaling to Erk1/2 activa-
tion, including after B3-AR stimulation, via either PKA or Src protein
kinase activation [28,29]. However, other authors have shown that
B3-AR-induced Erk1/2 activation is sensitive to pertussis toxin,
suggesting coupling with a Gi-protein [7,30,31]. In this case, the pro-
posed signaling involves the activation of an Src/PI3K-dependent
pathway [8]. The ability of PKA to induce a Gs/Gi coupling switch by
phosphorylating GPCRs, leading to receptor internalization and sub-
sequent desensitization, has been reported, but the B3-AR lacks the
PKA phosphorylation consensus sequence, which is present on the
B2-AR, for instance [9,32–34]. However, in a murine model of
B3-AR-transfected T1/2 preadipocytes, it has been suggested that
the activation of the Src protein kinase family could trigger the cou-
pling of the B3-AR with Gs and Gi simultaneously [35].
In the present study, we used an in-vitro approach to test the hy-
pothesis that the B3-AR is able to induce the proliferation ofmyometrial
cells.
2. Materials & methods
2.1. Materials
LPS (Escherichia coli 055:B5, ref L2880), U0126 (ref U120-1),
8-Br-cAMP (ref B7880), Forskolin (fromcoleus forskohlii, ref F6886), per-
tussis toxin (ref P7208), melittin (from honey bee venom, ref M2272)
genistein (synthetic, ref G6649), PP2 (ref P0042), H-89 (dihydrochloride
hydrate, ref B1427), Triciribine (hydrate, ref T3830), wortmannin (from
Penicillium funiculosum, ref W1628) and propranolol (hydrochloride, ref
P0884) were purchased from Sigma-Aldrich. PKA inhibitor peptide (ref
V5681) was purchased from Promega. SAR150640 was a gift from
Sanoﬁ-Midy Research Centre, Exploratory Research Department,
Sanoﬁ-Aventis S.p.A. SAR150640was dissolved in amixture of 30% abso-
lute ethanol, 2% dimethyl sulphoxide (DMSO) and distilled water for the
10−3 M solution and thereafter diluted in distilled water. The ﬁnal max-
imal bath concentration was 0.3% for ethanol and 0.02% for DMSO.
2.2. Primary cell lines
Myometrial cell lines were established from human myometrial
biopsies obtained from women undergoing elective Caesarean deliv-
ery for uncomplicated pregnancies with cephalopelvic disproportion,
prior the onset of labor (Centre Hospitalier et Universaire de Dijon,
Gynecology & Obstetrics Department). The biopsies were cut into
small strips (1 mm3) and cultured in DMEM supplemented with
20% FBS, 100 IU/ml PSA, 37 °C 5% CO2. After 2 to 3 weeks of culture,
the myometrial smooth muscle cells had reached conﬂuence. The ex-
plants were then gently removed; the cells harvested and put into
new culture plates, containing 10 ml DMEM 10% FBS 100 IU/ml PSA.
All of the experiments were performed on myometrial cell lines
from the 3rd to the 7th passage. This study was approved by the
local ethics committee (CPP, Dijon, France) and regulatory authori-
ties, and written informed consent was obtained from each donor.
2.3. Stimulation protocol
The myometrial cells were seeded in Ø100 mm dishes (2×105 cells/
10 ml), 6-well plates (106 cells/3 ml) and 24-well plates (105 cells/1 ml)
for ﬂow cytometry, Western blotting and immuno-ﬂuorescence analy-
ses, respectively. The cells were allowed to adhere for 24 h in complete
medium, 37 °C, 5% CO2, before 48 h starvation with low glucose (1 g/l)
DMEM without phenol red and L-glutamine to synchronize the cells in
the G0 phase of the cell cycle, and to reach a basal MAPK phosphoryla-
tion level. After starvation, the cells were stimulated for variable dura-
tions (3 min to 48 h) and with variable concentrations of SAR150640
(10−5 to 10−9 M), as indicated in the ﬁgure legends. Negative andpositive controls were performed for each experiment using 100 μl of
SAR150640 vehicle (H2O 20% ethanol, 2% DMSO) and 10% FBS supple-
mented medium, respectively. Short stimulations (less than 1 h) were
performed in the starvation medium, to avoid MAPK phosphorylation
induced by the addition of fresh medium. Longer stimulations (1 to
48 h) were performed in Opti-MEM without antibiotics. All inhibitors
were added 1 h prior to SAR150640 treatments, as indicated in the indi-
vidual experiments, except for melittin, which was added at the time of
SAR150640 treatment.
2.4. Cell proliferation analysis
After stimulation, myometrial cell proliferation was assessed by
ﬂow cytometry, using propidium iodide labeling. Brieﬂy, the culture
medium was removed and the cells were harvested and plated in
15 ml conical tubes. The pellets were re-suspended in 250 μl of trysin
buffer (Spermin tetrahydrochloride, citrate, and trypsin) and incubat-
ed for 13 min at room temperature (RT), away from light. 200 μl of
RNase buffer (Spermin tetrahydrochloride, citrate, trypsin inhibitor,
RNase from bovine pancreas) were then added, and the samples
were incubated for 10 min at RT, away from light. 25 μl of propidium
iodide (PNN-1001, Invitrogen) was ﬁnally added before ﬂow cytome-
try analysis. 250 μl of cell preparation was then placed in 96-well
plates, and analyzed with a guava Easycyte® plus ﬂow cytometer. A
primary gating was performed on a Size-Granularity dot plot to dis-
criminate cells from debris, and a secondary gating was performed
on a Red-Area–Red-Width dot plot to discriminate single cells from
doublets (see Supplementary methods). Cell proliferation was
obtained by measuring the volume of each preparation needed to
reach 10000 events in the secondary gate. Cell-cycle phase was eval-
uated by measuring propidium iodide labeling intensity, which is
proportional to the DNA contained in each cell, and the S-phase
ratio was quantiﬁed using modﬁt LT 3.3® software.
2.5. Western blotting analysis
After treatments, the plateswere immediately put on ice, themedium
was aspirated, and cells were lysed directly in the well by the addition of
100 μl of cold RIPA buffer (50 mM Tris–HCl pH 7.4, 150 mMNaCl, 1 mM
EDTA, 1% TritonX-100, 1% Sodium deoxycholate, 0.1% SDS, protease and
phosphatase inhibitor cocktail). Lysates were scraped and transferred to
1.5 ml conical Eppendorf tubes, and sonicated for 10 s. After the addition
of 25 μl 5× laemmli buffer (0.5 M Tris–HCl, pH 6.8, 10% (w/v) SDS, 20%
glycerol, 5%β-Mercaptoethanol, 0.5% Bromophenol blue (w/v)), the sam-
ples were heated for 4 min at 95 °C. 30 μg of total proteins were then
separated on 10% polyacrylamide gel, and transferred to PVDF mem-
branes. After transfer, non-speciﬁc binding siteswere blockedby incubat-
ing the membranes for 1 h at RT in TBS-tween 0.1%, non-fat dry milk 5%
and BSA 0.1%. The membranes were then incubated for 1 h 30 min at RT
with the primary antibodies, rabbit polyclonal anti-cyclinD1, rabbit
polyclonal anti-cyclinE, rabbit polyclonal anti-Erk1/2, rabbit polyclonal
anti-Akt, rabbit polyclonal anti-Phospho-Erk1/2, rabbit polyclonal anti-
Phospho-Akt (Cellsignaling technologies, #2978, #4129, #9102, #9272,
#9101, #9271, respectively), and rabbit polyclonal anti-GAPDH
(SC-25778, Santacruz Biotechnologies), (1/1000 dilution in the blocking
solution). The primary antibodies were detected by incubating themem-
branes for 1 h with horseradish peroxydase-coupled secondary donkey
anti-rabbit antibody (SC-2357, Santacruz Biotechnologies, CA, USA),
(1/10,000 dilution in the blocking solution), and chemoluminescence
induced by incubating for 1 min in ECL reagent (SC-2048, Santacruz
Biotechnologies). The membranes were then exposed to Kodak ﬁlms
for 3 to 7 min. The ﬁlmswere ﬁnally digitized using a GS-800 densitom-
eter, and the bands were quantiﬁed with quantity one® software. For
cyclin expression, the quantiﬁed bands were normalized with GAPDH,
and for phosphorylation assays, the bands were normalized with the
total form of the corresponding protein.
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Before stimulation, the cells were ﬁrst cultured in 24-well plates
containing sterile Ø13 mm microscope coverslips. After stimulation,
the plates were immediately put on ice, the medium was aspirated,
and the cells ﬁxed directly in the well by the addition of 1 ml cold PBS
2% paraformaldehyde solution, and incubated for 5 min at 4 °C. After
ﬁxation, the cells were blocked and permeabilized by adding 1 ml
PBS, 1% BSA and 0.1% saponin solution and incubated for 10 min at RT.
The cellswere then incubated overnight at 4 °Cwith primary polyclonal
anti-phospho-Erk1/2 rabbit antibody (1/200 dilution in the blocking so-
lution). Primary antibodies were detected using an Alexasﬂuor 488
coupled donkey anti-rabbit antibody (A-21206, Invitrogen), (1/500 di-
lution in PBS 10% blocking solution), incubated for 30 min at RT, away
from light. Nuclear labeling was also performed by incubating the
cells in a PBS, DAPI (1 ng/ml) solution for 30 s at RT, away from light.
The coverslips were then gently removed, and mounted onto a
superfrost slide, in a Dako anti-fading mounting medium. The slides
were ﬁnally observed with a Nikon (E400, Eclipse) epiﬂuorescence mi-
croscope. Five pictures were taken in random ﬁelds for each labeling,
and analyzed using imageJ software.
2.7. B3-AR silencing
The B3-AR was silenced in myometrial cells using the siRNA re-
agent system (SC-45064, Santa Cruz Biotechnologies) following the
manufacturer's instructions. Brieﬂy, myometrial cells were seeded
on 6-well plates and transfected after reaching 60–80% conﬂuence,
for 8 h. The B3-AR was knocked down using three speciﬁc sequences
(B3-AR siRNA, Santa Cruz Biotechnologies, SC-105010), and a control
was performed using non-speciﬁc sequences control siRNA A
(SC-37007, Santa Cruz Biotechnologies). The cells were reseeded
with 1 ml transfection medium for 18 additional hours before the
stimulation protocol. For ﬂow cytometry analysis, cells were seeded
and starved for 24 h, then transfected for 24 additional hours in ab-
sence of FBS before stimulation with SAR150640.
2.8. Statistical analysis
Differences among groups were determined by ANOVA followed
by Bonferroni's multiple comparison test. Statistical analysis was car-
ried out using SigmaStat version 3 (GraphPad Software). All differ-
ences were considered signiﬁcant when pb0.05.
3. Results
3.1. B3-AR stimulation induces HM-SMC proliferation
We ﬁrst aimed to characterize in detail the proliferative effects of
B3-AR stimulation in a primary culture of myometrial smooth muscle
cells. We thus used SAR150640, a highly selective B3-AR agonist
(Ki=73nM), that was shown to have no afﬁnity for B1- and B2-AR in
more than 60 human models (including the human myometrium)
[12]. In line with the proliferative effects observed in other cell types,
we found that 48 h of stimulation with SAR150640 induced a dose-
dependent increase in cell number (Fig. 1A) and S-phase ratio
(Fig. 1B), with a maximal effect at 10−7 M showing a 21%±3.61 in-
crease in cell number, when compared with unstimulated cells.
To better characterize the cell-cycle phase involved in this effect,
we studied cyclin expression and observed, after 8 h of stimulation,
a 4.4±1.0-fold increase in the relative expression of cyclin D1 (G0
to G1 transition phase) and a 4.7±1.2-fold increase in the relative ex-
pression of cyclin E (G1 to S transition phase) vs. untreated cells
(Fig. 1C, D, E).
Speciﬁcity of the B3-ARmediated effect of SAR150640Awas assessed
using two complementary approaches. First, we used propranolol, acommonly used beta-blocker that has been described to have a high af-
ﬁnity for the B1- and B2-ARs, and a lower afﬁnity for the B3-AR. Thus,
using propranolol at two concentrations, 10−7 and 10−5 M will inhibit
B1- and B2-ARs only, or all B-AR subtypes respectively [36].We observed
that, whereas inhibiting B1- and B2-AR with propranolol 10−7 M had
virtually no effect on SAR150640-induced proliferation, propranolol
10−5 M antagonized the effects of SAR 150640 on cell number increase
(Fig. 1 F). We also observed a strong repressive effect of B3-AR speciﬁc
siRNA on SAR150640-induced cell number increase (Fig. 1G) and cyclin
D1 and E overexpression (Fig. 1H, I, J). Collectively, these data indicate
that SAR150640 induces B3-AR speciﬁc myometrial smooth muscle cell
proliferation by inducing the early steps of the cell cycle (G0/G1 then
G1/S transition).
3.2. Β3-AR stimulation by SAR150640 induces biphasic Erk1/2 activation,
and ﬁnal Akt activation
As it is generally reported that B3-AR induces cell proliferation, via
either Erk1/2 or Akt activation, we next measured the abundance of
the phosphorylated forms of Erk1/2 and Akt in response to B3-AR
stimulation in myometrial smooth muscle cells. We performed a
time course stimulation and observed ﬁrst a strong (8.24±1.55-fold
increase vs. CTL) induction of Erk1/2 phosphorylation in response to
SAR150640, which appeared at 2 min and peaked after 3 min of stim-
ulation (Fig. 2A, B). This Erk1/2 phosphorylation was associated with
its translocation into myometrial smooth muscle cell nuclei (Fig. 2C)
indicating the full activation of Erk1/2. We then observed that this
ﬁrst activation phase was followed by a strong and prolonged de-
crease in Erk1/2 activation (Fig. 2D, E).
Finally, we observed that SAR150640 induced a second and lower
wave of Erk1/2 phosphorylation (1.6±0.02-fold increase vs. CTL)
after 8 h of stimulation (Fig. 2 F, G). No induction of Erk1/2 was ob-
served after 24 or 48 h of stimulation.
Interestingly, while SAR150640 did not induce Akt phosphorylation
during the short (Fig. 2A, B) or medium time-course experiments
(Fig. 2D, E), a moderate increase in Akt phosphorylation was observed
after 48 h of stimulation (1.57±0.18-fold increase vs. CTL, Fig 2 F andG).
3.3. Erk1/2, but not Akt-activation mediates B3-AR-induced proliferation
To test the hypothesis that Erk1/2 or Akt are required to trigger
B3-AR-induced myometrial smooth muscle cell proliferation, we
performed co-stimulations with the MEK1/2 inhibitor, U0126, or
with the Akt inhibitor, triciribin. Flow cytometry analysis revealed
that the blockade of MEK1/2 fully inhibited the effect of SAR150640
on cell number and S-Phase increase (Fig. 3A, B, respectively). West-
ern blot analysis conﬁrmed the inhibitory effect of MEK on Erk1/2 ac-
tivation (Fig. 3C) and demonstrated that MEK1/2 inhibition abolished
SAR-150640-induced cyclin D1 protein expression (Fig. 3C, D) and
partially inhibited cyclin E protein expression (Fig. 3C, E).
Western blot analysis conﬁrmed the inhibitory effects of triciribin
on Akt phosphorylation after 48 h of stimulation with SAR150640
(Fig. 3 F). However, Akt inhibition had no signiﬁcant effect on cell
proliferation (Fig. 3G).
These data indicate that Erk1/2 (but not Akt) is required for B3-AR
stimulation to induce human myometrial smooth muscle cell prolif-
eration, and also that the induction of cyclin D1 and E expression pre-
viously observed is under the control of Erk1/2.
3.4. The ﬁrst phase of Erk1/2 activation is Gs-dependent
Erk1/2 is an important signaling intermediate in cell proliferation
that can be activated by a wide variety of effectors. As mentioned,
B3-AR-induced activation of Erk1/2 has been linked to the activation
of either a Gs/cAMP/PKA or a Gi/PI3K/Src pathway. We thus aimed to
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myometrial smooth muscle cells.
We ﬁrst studied the 2 to 5-minute peak of Erk1/2 activation. In line
with our previous work, which demonstrated Gs coupling of the B3-AR
in the human myometrium, we observed that both forskolin, a direct
activator of adenylyl cyclase, and 8-Br-cAMP, the stable analogue of
cAMP, activated Erk1/2 after 3 min of stimulation (Fig. 4A, B). More-
over, co-stimulation with the Gi inhibitor pertussis toxin (PTX,200 ng/ml) showed that neither forskolin-, nor SAR150640-induced
Erk1/2 activation were sensitive to Gi inhibition (Fig. 4C, D).
We also studied the activation of PKA in response to B3-AR stimu-
lation. Western blot analyses revealed that PKA phosphorylation level
increased within 2 to 5 min in response to SAR150640 (see Supple-
mental data 1A) andwas released from a peri-nuclear location (corre-
sponding to inactive PKA) into the cytoplasm (see supplemental data
1B). Moreover, PKA activity, monitored using the Promega Peptag
0
0,2
0,4
0,6
0,8
1
1,2
1,4
1,6
0' 5' 15' 30' 45' 60'
Fo
ld
 in
cr
ea
se
 v
s.
  C
TL
SAR150640 10-7 M
p-Erk1/2
p-Akt
+ + +- --
p-Erk 1/2 42kD
Ser473 p-Akt 60kD
SAR150640
(10-7M)
48h8h 24h
F
P-Erk1/2
SAR150640 (10-7M) 
Time min
0 1 2 3 4 5
A
DAPI P-Erk1/2
C SAR150640
(10-7M)
0’
2’
3’
4’
5’
0
2
4
6
8
10
12
0 1 2 3 4 5
Tr
ac
e 
O
D 
v
s.
 C
TL
Time (min)
p-Erk1/2
p-Akt
Ser473 P-Akt
B
*
**
*
**
p-Erk 1/2 42kD
Ser473 p-Akt 60kD
0’ 5’ 15’ 30’ 45’ 60’
SAR150640 (10-7M) 
D
Akt
Erk 1/2 42kD
Akt 60kD
Erk1/2
Erk 1/2
Akt
42kD
60kD
0
0,2
0,4
0,6
0,8
1
1,2
1,4
1,6
1,8
2
Fo
ld
 in
cr
ea
se
 v
s.
 C
TL
P-Erk 1/2
P-Akt
* *
E
SAR150640
(10-7M)
+ + +- --
48h8h 24h
G
*
*
44kD
44kD
44kD
44kD
42kD
60kD
42kD
60kD
44kD
44kD
Fig. 2. SAR150640 induces biphasic activation of Erk1/2, and ﬁnal activation of Akt. A, D & F: Western blots p-Erk1/2 and p-Akt blots: Myometrial cells were cultured with SAR150640
(10−7 M) for 0–5 min (A), 0–60 min (D) and 8–24 h (F). Presented blots are representative of 6 independent experiments. B, E & G: Quantiﬁcations: 42 kDa p-Erk and 60 kDa p-Akt
bands were digitized and quantiﬁed with Quantity one. Phosphorylated bands are compared with total form bands for each condition and represented as mean values±SEM. n=6.
*=pb0.05 vs. CTL. **=pb0.01 vs. CTL C: P-Erk immuno-ﬂuorescence: Fixed cells were labeledwith an anti-P-Erk1/2 antibody alexas488, andwith DAPI for nuclear localization. Pictures,
taken with an epiﬂuorescence microscope (×400) in random chosen ﬁelds, are representative of ﬁve pictures taken for each condition. N=4.
1045T. Hadi et al. / Biochimica et Biophysica Acta 1833 (2013) 1041–1051Assay®, was also increased in response to SAR150640 stimulation
within 2 to 5 min (see Supplemental data 1C).
We also performed co-stimulations with the toxin melittin, which
reportedly inhibits Gs protein, but is a potent activator of Gi [37]. For
this reason, it was added concomitantly with SAR150640. Interesting-
ly, we observed that 3 min of co-stimulation with melittin abolished
both basal and B3-3AR-induced Erk1/2 phosphorylation (see supple-
mental data 2A, B). Collectively, these data indicate that the ﬁrst peak
of Erk1/2 activation is Gs-dependent but completely Gi-independent.
Finally, we performed co-stimulationswith the inhibitors of PKA and
Src, namely H89 (5 μM) and PP2 (10 μM), respectively (Fig. 4E), and ob-
served that both inhibitors abolished SAR150640-induced Erk1/2 phos-
phorylation at 3 min, indicating a classical Gs/cAMP/PKA/Src activatingpathway. Further experiments were carried out using a peptidic inhibi-
tor of PKA (20 μM), also showing an abolition of Erk1/2 phosphorylation
(see supplemental data 1D).
3.5. The second wave of Erk1/2 activation is Gi-dependent
The same approach was used to assess the pathway involved in the
secondwave of Erk1/2 activation, occurring within 8 h of B3-AR stimu-
lation, andwe observed that it was abolished by PTX co-stimulation, in-
dicating Gi dependent Erk1/2 activation (Fig. 5A, B). Contrary to what
was found during the ﬁrst peak of Erk1/2 activation, we observed that
the second wave of activation remained unaffected by PKA inhibition
with H89 (Fig. 5C, D). This suggests that PKA, which is required for
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after 8 h of stimulation, and that theﬁrst peak of Erk1/2 activation is not
needed for the second to occur. In contrast, we observed that Src inhibi-
tion with PP2 abolished SAR150640-induced Erk1/2 activation at 8 h
(Fig. 5C, D), as was the case for Erk1/2 activation at 3 min, indicating
that Src plays a role in both phases of Erk1/2 activation.
As the B3-AR-mediated Gi/PI3K/Src-dependent activation of Erk1/2
had already been described, we also performed co-stimulations using
the PI3K inhibitor wortmannin (WTM). We observed that WTM
abolished Erk1/2 phosphorylation observed after 8 hours of SAR150640
stimulation, (Fig. 5C, D), whereas no effect of PI3K inhibition was seen
on the 3-minute Erk1/2 phosphorylation peak (data not shown).
Finally, melittin per se induced a strong activation of Erk1/2 at 8 h,
with no further enhancement in cases of co-stimulation withSAR150640 (see supplemental data 2C, D). The Gi protein inducing
effects of melittin probably explains this strong induction of Erk1/2
phosphorylation observed after 8 h of stimulation. Collectively,
these results indicate that the second peak of Erk1/2 activation de-
pends on a Gi/PI3K/Src-dependent mechanism, and is Gs and PKA
independent.
3.6. Gs and Gi activation are both required to induce myometrial cell
proliferation
As we identiﬁed two B3-AR dependent pathways leading to Erk1/2
activation, at two different time points, we ﬁnally aimed to identify
which pathway was required to induce myometrial smooth muscle
cell proliferation. We performed 48 h of co-stimulation with either a
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tein, by melittin and PTX, respectively, abolished SAR150640-induced
proliferation (Fig. 6A, B), indicating that both pathways are required
for B3-AR stimulation to induce proliferation. Therefore, both waves of
Erk1/2 activation are needed to obtain myometrial smooth muscle cell
proliferation.
When H89 was used, we observed that PKA, whose activation is not
involved in the secondwave of Erk1/2 phosphorylation (Fig. 5C), is need-
ed to trigger the ﬁnal proliferative effect (Fig. 6C), once again, similar re-
sults were obtained using the PKA peptide inhibitor (see Supplemental
data 1E). In contrast, PI3K inhibition by WTM, which had no impact on
the ﬁrst phase, but blocked the second wave of Erk1/2 activation, also
blocked SAR150640-induced proliferation (Fig 6C). As expected, the in-
hibition of Src, which is involved in Erk1/2 activation at both 3 min and
8 h, also abolished the proliferative effects of B3-AR stimulation
(Fig. 6C). Thus, we demonstrated that the blockade of Src, PI3K, and/orPKA blocked B3-AR-induced proliferation of human myometrial cells,
conﬁrming that both the Gs/cAMP/PKA and Gi/PI3K/Src pathway are
required.
Finally, to further support these results, we performed a sequential
inhibition of the two Erk1/2 activation peaks using U0126 (A schematic
representation of the experiment is presented on Fig. 6D). We observed
that inhibition of either theﬁrst or the second Erk1/2 activation lead to a
full blockade of SAR150640-induced cell proliferation (Fig. 6E), con-
ﬁrming the requirement of the two Erk1/2 activation peaks in the
B3-AR-induced proliferative signaling.
4. Discussion
The B3-AR has been studied over the past decades for its potential
therapeutic interest in several conditions such as cachexia, metabolic
syndrome, obesity, diabetes, cardiac diseases, and more recently in
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tive effects of the B3-AR could also be a therapeutic approach in some
of these diseases. For example, by inducing hippocampal neuronal pro-
genitor proliferation, the B3-AR may be of interest in the treatment of
depression [22]. It is also able to induce choroidal cell proliferation,
and could thus prevent damage in cases of diabetic retinopathy [8]. Ad-
ditionally, the proliferative effect on myometrial smooth muscle cells
could be beneﬁcial by maintaining uterine contractile quiescence. The
ﬁrst ﬁnding of interest in the present study is that B3-AR stimulation
induces the proliferation of human myometrial smooth muscle cells.
The second ﬁnding is that we propose a new signaling mechanism
by which B3-AR stimulation induces a proliferative effect involving
biphasic Erk1/2 activation triggered by the sequential activation of the
Gs/cAMP/PKA and Gi/PI3K/Src pathways.
4.1. Proliferative effects of the B3-AR
4.1.1. Erk1/2 dependent induction of cyclin D1 and E expression
Among the mitogenic associated protein kinase (MAPK) pathways,
which are responsible for both cell cycle induction and regulation, the
Erk1/2 pathway has been extensively studied [39–41]. Recent studies
have highlighted a strong link between Erk1/2 activation and cyclin
D1 and then cyclin E expression, which is involved in G0 to G1 and G1
to S cell cycle phase transition, respectively. Indeed, Erk1/2 activates
the transcription factor AP-1 and inactivates the repressor Tob [42,43]
[41–43], respectively promoting and inhibiting cyclin D1 expression.
In turn, cyclin D1, by activating its targets, the two cyclin-dependent ki-
nases 4 & 6, will lead to the induction of cyclin E expression [44]. In this
report, we have shown that SAR150640-induced myometrial smooth
muscle cell proliferation depends on the induction of cyclin D1 and E
expression, but not of cyclin B1, which is involved in G2 toM transition.
Whereas previous papers described, aswe have here, an Erk1/2-depen-
dent proliferative effect of the B3-AR [39,42,43], they did not assess its
impact on the induced expression of different cyclins. Our results indi-
cate for the ﬁrst time that the proliferative effect of the B3-AR could
be mediated by the speciﬁc induction of the early steps, G0/G1 andG1/S transitions, of the cell cycle. Moreover, in line with data from the
literature, we observed that Erk1/2 blockade fully inhibits B3-AR in-
duced cyclin D1 and E expression.
4.1.2. The B3-AR induces a biphasic Erk1/2 activation
Whereas Erk1/2 activation has also been reported to trigger other
processes such as apoptosis, inﬂammation or differentiation [39]. Our
team has previously shown that B3-AR stimulation was able to pre-
vent myometrial inﬂammation and apoptosis. This apparent discrep-
ancy has already been observed, and seems to be due to the kinetics
and the degree of Erk1/2 phosphorylation. For example, Kahan et al.
[45] reported that the biphasic activation of Erk1/2, with an early
(1–10 min) strong peak of activity, followed by a second sustained
phase of lower activity (over several hours) is needed to induce pro-
liferation, whereas Tombes et al. reported that the acute and
prolonged phosphorylation of Erk1/2 is associated with the induction
of cell cycle arrest and inﬂammation [46]. No formal explanation has
been made for this phenomenon; however, it has been suggested that
the pathways leading to Erk1/2 phosphorylation, mediated either by
B-raf or Raf-1 could trigger these opposite effects [46]. In this study
we have reported that B3-AR-dependent Erk1/2 phosphorylation
was biphasic with peaks at 3 min and 8 h. Thus, given this biphasic
activation with both the anti-inﬂammatory and anti-apoptotic effects
previously observed, these results suggest that B3-AR-induced Erk1/2
activation would maintain myometrial smooth muscle cells prolifera-
tion, and thus uterine quiescence. Late Akt activation, at a time where
Erk1/2 is no longer activated by B3-AR stimulation, in combination
with the fact that its inhibition with Triciribin had no or little effect
on B3-AR-induced proliferation, suggests that Akt has a role in the
early phase of B3-AR-induced proliferation, as has been suggested
for other adrenergic receptors [23,47]. However, it is noteworthy
that after 48 h of stimulation, a time at when Akt is activated, but
no longer Erk1/2, the proportion of cells in the S-phase is still higher
in the SAR150640-stimulated cells than in untreated cells, indicating
that the proliferative effect of SAR150640 is sustained for at least
48 h, and suggesting that Akt may play a role in this latter step.
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4.2.1. Sequential Gs then Gi signaling
The major ﬁnding of this study is that the biphasic activation of
Erk1/2 in myometrial smooth muscle cells depends on the sequential
activation of the Gs and then Gi pathway. This ability of the B3-AR to
couple ﬁrst to a Gs then to a Gi protein could explain the absence of
consensus observed regarding B3-AR coupling and subsequent sig-
naling. Interestingly, Bronnikov et al. [25] and Lindquist et al. [26],
who both proposed Gs coupling, focused their demonstration on eval-
uating the increase in cAMP production or Erk1/2 activation after a
short time (5 min) of B3-AR stimulation. Moreover, Lindquist et al.
[26] demonstrated that this early activation of Erk1/2 was PTX insen-
sitive but did not assess the impact of PTX on ﬁnal B3-AR-mediated
proliferation. In this context, the 3 min signaling for Erk1/2 activation
associated with Gs signaling observed in our study is in keeping withtheir ﬁndings. In contrast, authors that have focused on the ﬁnal effect
of the B3-AR rather than on the early activation pathway concluded
that Gi coupling was involved. First, Anesini et al. [21] and Robay et
al. [27] both investigated the effect of the B3-AR on cells stimulated
for more than 15 min to assess the activation of ion channels. In
this context, they observed that B3-AR-induced ion channel activa-
tion was PTX sensitive and associated with a decrease in cAMP con-
centrations. The results in our study are in line with these data,
since we observed that the ﬁrst 3 min signaling was followed by a
decrease in both Erk1/2 and PKA activation, and that Gs/cAMP/PKA
signaling was no longer needed to lead to the second wave of Erk1/2
activation. Finally, Steinle et al. [8,23] demonstrated that blocking
the Gi, PI3K, Src and Erk1/2 pathway for 48 h fully inhibited B3-
AR-mediated choroidal cell proliferation, and thus proposed a Gi/PI3K/
Src/Erk1/2 pathway in the retina. Once again, we observed the same re-
sults for B3-AR-inducedmyometrial cell proliferation, but also observed
1050 T. Hadi et al. / Biochimica et Biophysica Acta 1833 (2013) 1041–1051that this Gi/PI3K/Src-induced activation occurred during the second
peak of Erk1/2 phosphorylation.4.2.2. Role of Src
Our study also highlights the involvement of Src in B3-AR-mediated
proliferation. The activation pathway of the Src protein kinase family
still remains unclear. It has been shown that Src present two phosphor-
ylation sites, Tyr416, and Ser17, both of which enhance Src activity [48].
Ser17 is believed to be a site for phosphorylation by PKA [49]. In the
present study, we observed phosphorylation of the Tyr416 site in re-
sponse to B3-AR stimulation. In contrast, no phosphorylation of Ser17
(PKA-dependent site) was observed (see Supplemental data 1). These
data suggest that Src activation occurs independently and upstream of
PKA activation. According to our results, Src plays a crucial role in both
phases of Erk1/2 activation, which led us to consider its potential role
in triggering the switch of coupling, a role that remains to be further elu-
cidated. One argument favoring the hypothesis of a Src-dependent
switch has been proposed by Cao et al. [35]. In a murine model of im-
mortalized T1/2 preadipocytes, they observed that over-expressed
B3-AR can directly recruit the protein kinase Src, leading to the activa-
tion of a Gi protein, and subsequent PI3K-dependent Erk1/2 activation.
According to their ﬁndings, B3-AR could thus be directly (Gs) and indi-
rectly (Gi) coupled to both G proteins [35].4.3. Conclusion
In conclusion, these data bring new insights into the proliferative
effects driven by B3-AR, and the new sequential activation of Gs and
then Gi (summarized in Fig 7) proposed here could explain the dis-
crepancies in the signaling pathways described in previous studies.
In light of our previous work, the present study emphasizes the
potential value of the B3-AR agonist, SAR150640, in the pharmacolog-
ical management of preterm labor, as it is able to maintain prolifer-
ation and to oppose the triggering mechanisms of labor, namely
remodeling [13], inﬂammation, apoptosis [14] and their conse-
quences (i.e myometrial contractions).
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.bbamcr.2013.01.019.B3-AR
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